ADAPTABLE RNA-BASED ANTIBODY PLATFORM FOR PROTECTION AGAINST CONTEMPORARY/EMERGING HUMAN ENTEROVIRUSES
$1,499,422
| Recipient | HDT BIO CORP UEI Z33DCMWXZBK7 |
|---|---|
| Award ID | 75N93022C00017 |
| Award amount | $1,499,422 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Health and Human Services — National Institutes of Health |
| NAICS | 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) |
| PSC | AN12 |
| Start date | Jul 1, 2022 |
| End date | Jun 30, 2025 |
| Place of performance | SEATTLE, WA |
| Record updated | Jul 1, 2022 |
View the official award record
More awards won by HDT BIO CORP
COVID-19. TO DEVELOP AND PROGRESS HDT-301, A REPLICON RNA ENCODING SARS-COV-2 SPIKE PROTEIN BOUND TO LIPID INORGANIC NANOPARTICLE (LION) FORMULATION TO PROTECT AGAINST COVID-19, THROUGH A PHASE I CLINICAL TRIAL.
Department of Health and Human Services · $10,970,058 · Sep 1, 2020
HDT BIO CORP - AOI #21 VACCINE ON DEMAND: R&D USE OF LION-REPRNA IN RAPID RESPONSE VACCINE DEVELOPMENT
Department of Health and Human Services · $749,000 · Sep 22, 2023
RATIONAL DEVELOPMENT OF A COMBINATION NANOPARTICLE ADJUVANT FOR INFLUENZA.
Department of Health and Human Services · $599,629 · Sep 1, 2019
Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.
Search open bids